Defence Therapeutics provides an update on its numerous anti-cancer projects - Health Europa

Biotechnology pioneers Defence Therapeutics outline its current research and development progress in a plethora of anti-cancer endeavours.

In Q1 of 2022, Defence signed an agreement with the Advanced Therapies Facilities (ATF) GMP Unit of The University of Birmingham to prepare its Dendritic Cell vaccine AccuVAC-D001M in accordance with… [+2201 chars]

full article...